Browsing by Author Bondarenko, I.


Showing results 1 to 5 of 5
Issue Year Title Author(s) Type Views Downloads
2022 Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study Felip, E.; Altorki, N.K.; Zhou, C.; Vallieres, E.; Vynnychenko, Ihor Oleksandrovych; Akopov, A.; Martinez-Marti, A.; Chella, A.; Bondarenko, I.; Ursol, G.; Levchenko, E.; Kislov, N.; Liersch, R.; Belleli, R.; McNally, V.A.; Bennett, E.; Gitlitz, B.J.; Wakelee, H. Conference Papers 4009127 5569260
2022 Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies Shah, M.A.; Udrea, A.A.; Bondarenko, I.; Mansoor, W.; Sánchez, R.G.; Sarosiek, T.; Bozzarelli, S.; Schenker, M.; Gomez-Martin, C.; Morgan, C.; Özgüroğlu, M.; Pikiel, J.; Kalofonos, H.P.; Wojcik, E.; Buchler, T.; Swinson, D.; Cicin, I.; Joseph, M.; Vynnychenko, Ihor Oleksandrovych; Luft, A.V.; Enzinger, P.C.; Salek, T.; Papandreou, C.; Tournigand, C.; Maiello, E.; Wei, R.; Ferry, D.; Gao, L.; Oliveira, J.M.; Ajani, J.A. Article 413609 56480
2021 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma Sahin, U.; Türeci, Ö.; Manikhas, G.; Lordick, F.; Rusyn, A.; Vynnychenko, Ihor Oleksandrovych; Dudov, A.; Bazin, I.; Bondarenko, I.; Melichar, B.; Dhaene, K.; Wiechen, K.; Huber, C.; Maurus, D.; Arozullah, A.; Park, J. W.; Schuler, M.; Al-Batran, S.-E. Article 1 0
2021 Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer Rugo, H.S.; Pennella, E.J.; Gopalakrishnan, U.; Hernandez‑Bronchud, M.; Herson, J.; Koch, H.F.; Loganathan, S.; Deodhar, S.; Marwah, A.; Manikhas, A.; Bondarenko, I.; Mukhametshina, G.; Nemsadze, G.; Parra, J.D.; Abesamis‑Tiambeng, M.L.T.; Baramidze, K.; Akewanlop, C.; Vynnychenko, Ihor Oleksandrovych; Sriuranpong, V.; Mamillapalli, G.; Roy, S.; Ruiz, E.P.Ya.; Barve, A.; Fuentes‑Alburo, A.; Walle, C.F. Article 0 0
2021 Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study Gafanov, R.; Powles, T.B.; Bedke, J.; Stus, V.; Waddell, T.S.; Nosov, D.; Pouliot, F.; Soulieres, D.; Melichar, B.; Azevedo, S.; McDermott, R.S.; Vynnychenko, Ihor Oleksandrovych; Borchiellini, D.; Markus, M.; Bondarenko, I.; Lin, J.; Burgents, J.; Molife, L.R.; Plimack, E.R.; Rini, B. Conference Papers 13882134 17079006